Proportional hazards general linear model analysis on major clinical transplantation endpoints
Covariates . | Leukemic relapse . | P . | Transplantation-related mortality . | P . | Overall survival . | P . | Event-free survival . | P . |
|---|---|---|---|---|---|---|---|---|
| Study group, relative risk (95% confidence limits) | < .008 | NS | NS | NS | ||||
| HLA class I and II identical | 1 | - | NR | - | NR | - | NR | - |
| HLA class I disparate, KIR ligand compatible | 0.49 (0.29-0.83) | - | NR | - | NR | - | NR | - |
| HLA class I disparate, KIR ligand incompatible | 0.24 (0.08-0.69) | - | NR | - | NR | - | NR | - |
| Disease stage, relative risk (95% confidence limits) | < .001 | < .001 | < .001 | < .001 | ||||
| Early disease stages | 1 | - | 1 | - | 1 | - | 1 | - |
| Advanced disease stages | 2.68 (1.61-4.74) | - | 3.02 (2.06-4.42) | - | 0.35 (0.25-0.48) | - | 0.36 (0.26-0.49) | - |
| Patient age/decade, relative risk (95% confidence limits) | NR | NS | 1.37 (1.13-1.65) | < .002 | 0.78 (0.66-0.92) | < .003 | 0.80 (0.68-0.93) | < .004 |
| Acute GVHD, relative risk (95% confidence limits) | NS | < .001 | < .001 | < .001 | ||||
| Grades 0-I | NR | - | 1 | - | 1 | - | 1 | - |
| Grades II-IV | NR | - | 3.59 (2.36-5.44) | - | 0.40 (0.28-0.56) | - | 0.47 (0.34-0.65) | - |
Covariates . | Leukemic relapse . | P . | Transplantation-related mortality . | P . | Overall survival . | P . | Event-free survival . | P . |
|---|---|---|---|---|---|---|---|---|
| Study group, relative risk (95% confidence limits) | < .008 | NS | NS | NS | ||||
| HLA class I and II identical | 1 | - | NR | - | NR | - | NR | - |
| HLA class I disparate, KIR ligand compatible | 0.49 (0.29-0.83) | - | NR | - | NR | - | NR | - |
| HLA class I disparate, KIR ligand incompatible | 0.24 (0.08-0.69) | - | NR | - | NR | - | NR | - |
| Disease stage, relative risk (95% confidence limits) | < .001 | < .001 | < .001 | < .001 | ||||
| Early disease stages | 1 | - | 1 | - | 1 | - | 1 | - |
| Advanced disease stages | 2.68 (1.61-4.74) | - | 3.02 (2.06-4.42) | - | 0.35 (0.25-0.48) | - | 0.36 (0.26-0.49) | - |
| Patient age/decade, relative risk (95% confidence limits) | NR | NS | 1.37 (1.13-1.65) | < .002 | 0.78 (0.66-0.92) | < .003 | 0.80 (0.68-0.93) | < .004 |
| Acute GVHD, relative risk (95% confidence limits) | NS | < .001 | < .001 | < .001 | ||||
| Grades 0-I | NR | - | 1 | - | 1 | - | 1 | - |
| Grades II-IV | NR | - | 3.59 (2.36-5.44) | - | 0.40 (0.28-0.56) | - | 0.47 (0.34-0.65) | - |
Covariates excluded by PHGLM analysis: underlying disease (CML vs AML/MDS), donor-recipient sex match (female-to-male transplantations vs other), donor age (per decade), graft type (bone marrow vs peripheral blood stem cells), donor source (related vs unrelated donor), donor type (HLA-identical versus HLA-partially matched), HLA-A allele disparity in graft-versus-host direction (no vs yes), HLA-B allele disparity in graft-versus-host direction (no vs yes), HLA-C allele disparity in graft-versus-host direction (no vs yes), any HLA class I allele disparity in graft-versus-host direction (no vs yes), number of HLA class I disparities in graft-versus-host direction (0-3), chronic GVHD (no vs yes, time-dependent).
- indicates not applicable; NR, proportional hazards not reported when P value was nonsignificant; and NS, nonsignificant.